Lose Weight With GLP-1 blog
Practical reporting on GLP-1 weight loss medications, telehealth providers, side effects, and pricing — from our editorial team.
GLP-1 microdosing — taking 0.05-0.125mg/week instead of standard 0.25-2.4mg — is trending. Here's what clinicians actually say, who offers it, and what it costs.
Published
Read →A new sham-controlled trial shows a minimally invasive gut procedure helped patients keep 80% of their GLP-1 weight loss after stopping tirzepatide. Here's what it means.
Published
Read →Fewer than 1 in 4 patients stay on a GLP-1 after one year. Up to 40% of weight lost is muscle. Each stop-restart cycle makes it worse. Here's what the research says — and how to avoid the trap.
Published
Read →NPR reports 12 million lost Zepbound coverage and 12 million lost Wegovy coverage in the past year. CVS Caremark, BCBS Massachusetts, and Harvard Pilgrim all pulled back. Here's the full list — and what you can do right now.
Published
Read →41 million Americans lost commercial GLP-1 coverage in 2026. CVS Caremark dropped Zepbound, BCBS restricted Wegovy. Here are the cheapest ways to keep your medication without insurance.
Published
Read →A massive 23andMe study published in Nature found genetic variants that predict GLP-1 weight loss (6-20%) and nausea risk (5-78%). Here's what it means for choosing your medication.
Published
Read →Hims partnered with Novo Nordisk, stopped advertising compounded GLP-1s, and now offers FDA-approved Wegovy starting at $149/month. Here's what changes for patients.
Published
Read →LillyDirect began shipping Foundayo on April 6, 2026. Here's exactly how to order, what it costs with and without insurance, and how it compares to every other GLP-1 option.
Published
Read →CMS's new Balance Model launches July 2026 as Medicare's first value-based GLP-1 coverage pilot. Here's what Part D patients need to know about eligibility and costs.
Published
Read →Foundayo ships April 6 at $149/month. Novo slashed Wegovy to $249. Medicare hits $50 in July 2026. Here's what every GLP-1 option actually costs right now.
Published
Read →Eli Lilly's oral weight loss pill got the fastest FDA approval since 2002 on April 1, 2026. Here's how Foundayo compares to oral Wegovy at $149/month.
Published
Read →Eli Lilly's oral GLP-1 pill gets its FDA decision April 10. Novo Nordisk just launched Wegovy subscriptions at $249/month. Here's what's happening now.
Published
Read →The $50/month Medicare GLP-1 Bridge launches July 1, 2026. Here are 5 things Part D enrollees must prepare now to lock in Wegovy, Zepbound, or Foundayo.
Published
Read →Three months after the December 2025 launch, here's what real oral semaglutide patients say about weight loss, side effects, and the fasting requirement.
Published
Read →The FDA's March 2026 enforcement wave adds 12 new compounding pharmacies to the warning list, bringing the total past 40 since late 2025. Here's who was flagged.
Published
Read →We tracked pricing across 15+ GLP-1 telehealth providers in March 2026. Here's who lowered prices, who raised them, and which compounded plan is cheapest now.
Published
Read →Eli Lilly's oral non-peptide GLP-1 orforglipron faces its FDA PDUFA date April 10, 2026. Here's how this pill could reshape the weight loss landscape.
Published
Read →